Search Results

descriptive review . Nat Clin Pract Oncol 2007 ; 4 : 643 – 656 . 29. Kuderer NM Dale DC Crawford J . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients . Cancer 2006 ; 106 : 2258 – 2266 . 30

Chemotherapy-induced neutropenia is hazardous for 2 reasons: it produces febrile neutropenia (FN), which may result in life-threatening infections and prolonged hospitalizations, and it can necessitate chemotherapy dose reductions and delays

alternative choices but rather avoiding use of the drug with chemotherapy regimens with a low risk of febrile neutropenia. 2 , 3 We agree with Dr. Burstein that a serious dialogue on cost-effective care is needed. Talk, however, is clearly not enough. We

. No white cell–stimulating factors for primary prevention of febrile neutropenia for patients with less than 20% risk for this complication. If the ancient adage, “First, do no harm” is still sacred, then the next line would be “Second, do no

amikacin as empiric therapy for febrile neutropenia . Clin Infect Dis 2001 ; 33 : 1295 – 1301 . 26 Gomez L Garau J Estrada C . Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of

benefit. As an example, the demonstration of efficacy for G-CSF agents may include absolute neutrophil counts, CD34 + cell counts, the duration of severe neutropenia (neutrophils <500 cells/μL), and rates of febrile neutropenia. However, surrogates may be

DLTs of grade 3 fatigue and grade 4 febrile neutropenia. 25 Based on the DLT noted in this trial and other phase II data available that showed no difference in toxicity or efficacy between the 2 doses of pertuzumab, the recommended phase II doses were

, to overcome any hesitancy among clinicians about the efficacy and safety of biosimilars, the new agent must have adequate clinical data showing comparability to the established agents in reducing the risk of severe febrile neutropenia. In anticipation

treated with docetaxel had significantly higher rates of febrile neutropenia and neuropathy, whereas in patients treated with carboplatin, vomiting appeared to be somewhat more common,” explained Dr. Telli. Furthermore, she said, “disappointingly, there

years) had improved median PFS and RR but no improvement in median OS. 11 The most common grade 3 or higher AEs in the bevacizumab arm were neutropenia (26%), hypertension (7%), febrile neutropenia (5%), and bleeding events (4%). 9 Compared with